Published in J Am Coll Cardiol on October 18, 2011
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction | NCT00433966
Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures | NCT02954029
The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol (2012) 2.31
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J (2014) 1.26
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. PLoS One (2013) 1.07
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J (2012) 1.06
Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention. J Am Heart Assoc (2013) 0.98
Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. Heart Vessels (2014) 0.89
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv (2012) 0.86
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol (2013) 0.78
Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. Int J Obes (Lond) (2015) 0.75
Impact of diabetes on bleeding events in ST-elevation myocardial infarction patients after urgent percutaneous coronary intervention: A retrospective cohort study. Medicine (Baltimore) (2016) 0.75
Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. J Atr Fibrillation (2015) 0.75
The impact of vascular access for in-hospital major bleeding in patients with acute coronary syndrome at moderate- to very high-bleeding risk. J Korean Med Sci (2013) 0.75
Long-term impact of periprocedural bleeding when does it end? J Am Coll Cardiol (2011) 0.75
Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study. Exp Clin Cardiol (2013) 0.75
Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med (2013) 24.88
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 19.90
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet (2004) 5.87
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol (2004) 5.67
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet (2012) 4.98
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (2003) 4.72
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension (2004) 4.56
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ (2013) 4.17
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
A family cluster of infections by a newly recognized bunyavirus in eastern China, 2007: further evidence of person-to-person transmission. Clin Infect Dis (2011) 3.91
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54
Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bull World Health Organ (2008) 3.33
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation (2012) 3.30
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 3.22
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol (2008) 3.13
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J (2005) 3.12
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
To retain or remove user fees?: reflections on the current debate in low- and middle-income countries. Appl Health Econ Health Policy (2006) 3.06
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97
Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet (2006) 2.92
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol (2013) 2.91